Proton Pump Inhibitors Could Get Boost From COX-2 Concerns OF FDA Cmte.

Combination therapy with non-selective NSAIDs and PPIs could be an attractive option in light of FDA advisory panel’s cardiovascular safety concerns about the entire COX-2 class. On the heels of the committee meeting, Santarus/Otsuka launch 40 mg dose of Zegerid omeprazole powder for oral suspension.